Angelini pharma
  • Group
  • Angelini Pharma
  • Who we are

    • Who We Are
    • Key facts and events
    • Vision, mission & values
    • People
  • Core areas

    • Rare Diseases
    • Mental Health
    • Consumer Health
  • From pipeline to health aids

    • Pipeline
    • Sites
  • Our Partnerships

    • Research & Academic Centers and Scientific Institutions
    • Partnering
  • Our Responsibility

    • Sustainability
    • Ethics
    • Quality policy
    • Transparency
  • Media

    • News
    • Press releases
    • Press kit
    • Magazine
    • Media center
  • Career Opportunities
  • Open main menu
  • Open main menu
  • Search

    Search

  1. Angelini Pharma
  2. Core areas
  3. Scientific Updates

Scientific Updates

Scientific Update
  • All articles
  • Mental Health
  • Pain
  • Rare Diseases
  • Consumer Health

Pain

  1. Undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain

    Breakthrough cancer pain (BTcP) is a transient condition in oncology patients.

    Undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain
load more

See also

  1. Rare Diseases

    Rare Diseases
  2. Mental Health

    Mental Health
  3. Consumer Health

    Consumer Health
Angelini pharma
  • Terms of use
  • Privacy
  • Transparency
  • Cookie Policy
  • Contact
  • Site map
  • Credits
  • Twitter
  • Linkedin
  • Facebook
  • Instagram
  • YouTube
  • Top Employee

Angelini S.p.a. - Viale Amelia 70, 00181 Roma - P.IVA 01258691003 e C.F. Numero di iscrizione registro imprese: 03907010585 - Ufficio del registro delle imprese: Roma - Capitale: € 165.000.000 I.V.
Copyright 2021 © Angelini S.p.a. - All Rights Reserved

Close menu